Extension Study of 1.0mg Dose Letrozole Therapy in Postmenopausal Patients With Breast Cancer
- To investigate the safety of letrozole monotherapy at a dose 1.0 mg/day or fadrozole monotherapy at a dose 2.0mg in Japanese postmenopausal patients with advanced breast cancer which participated in double blind study.
Postmenopausal Women With Advanced Breast Cancer
DRUG: Letrozole
Safety during treatment
No secondary outcomes/objectives planned
- To investigate the safety of letrozole monotherapy at a dose 1.0 mg/day or fadrozole monotherapy at a dose 2.0mg in Japanese postmenopausal patients with advanced breast cancer which participated in double blind study.